Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascentage Pharma Group International (AAPG) Retained Earnings (2023 - 2025)

Ascentage Pharma Group International posted quarterly Retained Earnings of -$988.8 million for Q4 2025, down 23.09% year-on-year from -$1.3 billion in Q4 2024, and down 23.09% on a QoQ basis from -$803.4 million in Q4 2024.

Ascentage Pharma Group International (AAPG) has 3 years of Retained Earnings data on file, last reported at -$988.8 million in Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings fell 23.09% year-over-year to -$988.8 million; the trailing twelve-month figure through Dec 2025 stood at -$988.8 million (down 23.09% YoY), and the FY2025 full-year result was -$1.0 billion, down 26.86% from the prior year.
  • Retained Earnings for Q4 2025 stood at -$988.8 million, down from -$803.4 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$745.1 million in Q4 2023 and bottomed at -$988.8 million in Q4 2025.
  • The 3-year median for Retained Earnings is -$803.4 million (2024), against an average of -$845.8 million.
  • The widest annual swing landed in 2024, when Retained Earnings fell 7.81%; it then fell 23.09% in 2025.
  • A 3-year view of Retained Earnings shows it stood at -$745.1 million in 2023, then fell by 7.81% to -$803.4 million in 2024, then dropped by 23.09% to -$988.8 million in 2025.
  • The last three Retained Earnings figures came in at -$988.8 million (Q4 2025), -$803.4 million (Q4 2024), and -$745.1 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Retained Earnings (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -211.85 Mn
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -153.89 Mn
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn 1.00 Bn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn - -438.66 Mn
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -279.00 Mn
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 14.59 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 36.42 Bn
8 Evaxion A 65.44 Bn 65.42 Bn - 130.89 Mn
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn -24.89 Mn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn - -988.83 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -988.83 Mn
Dec 31, 2024 -803.35 Mn
Dec 31, 2023 -745.15 Mn